Bluebird strikes a CAR-T deal with ViroMed; Ex-Allergan president takes over Chase Pharma;

@FierceBiotech: Q&A: Philips on what's next after the first year of HealthTech. More from FierceMedicalDevices | Follow @FierceBiotech

@JohnCFierce: This week we've been seeing the venture cash flowing. Bodes well for lots more action in 2016. | Follow @JohnCFierce

> Moving on from a scaled-back partnership with Celgene ($CELG), bluebird bio ($BLUE) signed a deal with ViroMed to develop CAR-T therapies for cancer, paying $1 million up front and promising up to $48 million per resulting product. News

> Former Allergan ($AGN) President Douglas Ingram has taken on the CEO role at Chase Pharmaceuticals, a privately held company developing treatments for neurological disorders include Alzheimer's disease. More

> KaloBios ($KBIO), the near-death biotech scooped up by Martin Shkreli, has fleshed out its management ranks with some leaders from Shkreli's privately held Turing Pharmaceuticals. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Syneron Medical bogged down with slumping sales for ultrasound fat-zapping device. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: AstraZeneca begins dosing in trial of its Bind-partnered cancer candidate. Story | Follow @VarunSaxena2

@EmilyWFierce: Check out this week's Dx Digest, featuring liquid biopsy news from Guardant Health and Circulogene Theranostics. Report | Follow @EmilyWFierce

> Novartis weighs sale of contact lens business as Alcon unit struggles to chart growth. More

> U.K.'s NHS funds 1,000+ patient trial of a minimally invasive artificial lung. Story

Pharma News

@FiercePharma: Flu expert warns against USDA move to build bird flu vaccine stockpile. Article | Follow @FiercePharma

@CarlyHFierce: @RepCummings to Shkreli: "To claim that a 50% discount after a 5,000% increase is a 'price cut' is Orwellian double-speak." | Follow @CarlyHFierce

> Japan poised to put 70% price lid on biosimilars, cap generics at 50% of reference drug. Story

> Struggling Eisai looks for help in China with new generics deal. More

CRO News

> Medidata reaches into South Korea with a CRO partnership. News

> Parexel revamps its trial management system for drugmakers large and small. Report

> INC's financiers bank another $272M in the IPO afterglow. More

> Survey: CRO employee turnover soars amid an industry boom. Story

> Quotient Clinical snapped up by Gillings-founded buyout firm. Article

Pharma Manufacturing News

> Wockhardt says U.K. regulatory agency issued GMP certificate to troubled Chikalthana plant. News

> EU agency gives Baxalta green light to begin manufacturing two plasma-based therapies. Story

> Radiopharmaceutical manufacturer Iason Italia hit with noncompliance report. Article

> FDA cites two Endo subsidiaries for product recalls. Report

> Danaher acquires German quality inspection firm Laetus for undisclosed price. Item

Pharma Asia News

> India's GVK Bio gets infusion of cash from ChrysCapital. Item

> Generic drugs face April 2016 price caps in Japan. More

> Ascletis gets $20M from Goldman in race to China HCV approval. Report

> Singapore researchers close in on 'liquid biopsy' to track cancer progress, treatment. Story

> BMJ: Drugmakers get quid pro quo for participation in Indian health camps. Article

Suggested Articles

The financing sets AM-Pharma up to advance in sepsis-associated acute kidney injury independently now Pfizer has turned down its option to buy.

The FDA sent Eton's partner, Bausch Health, a complete response letter that raised “no concerns” about the clinical data in the drug’s application.

A new partnership will test drug cocktails containing Karyopharm's new product Xpovio in cell samples from glioblastoma patients.